ABeta amyloidosis, Arctic type

ABeta amyloidosis, Arctic type (also called Arctic Alzheimer disease or Arctic APP mutation) is an extremely rare inherited form of early-onset Alzheimer disease. It is caused by a specific change (mutation) in the APP gene, which provides instructions for making amyloid precursor protein. This mutation leads to the production of an abnormal form of amyloid-beta protein that clumps together more easily than normal, forming deposits (called amyloid plaques) in the brain. These deposits damage brain cells over time, leading to progressive dementia. The disease typically begins in a person's 50s or early 60s, though some cognitive changes may appear earlier. Early symptoms often include memory problems, especially difficulty remembering recent events. Over time, the disease progresses to include confusion, difficulty with language and speech, personality changes, trouble with planning and decision-making, and eventually loss of the ability to care for oneself. The disease follows a course similar to typical Alzheimer disease but tends to start at a younger age. There is currently no cure for Arctic-type ABeta amyloidosis. Treatment focuses on managing symptoms and supporting quality of life. Medications used in typical Alzheimer disease, such as cholinesterase inhibitors and memantine, may be tried to help with cognitive symptoms, though their effectiveness in this specific genetic form has not been well studied in large trials. Research into amyloid-targeting therapies is ongoing and may hold future promise for patients with this condition.

Bring these to your next appointment

• Q1.How certain is the diagnosis, and should other family members be tested for this mutation?,What is the expected timeline for disease progression in my specific case?,Are any of the newer Alzheimer disease treatments (like anti-amyloid antibodies) appropriate for this specific genetic form?,Are there any clinical trials I might be eligible for?,What support services are available for me and my family as the disease progresses?,When should we start planning for advanced care needs and legal matters?,What should my family members know about genetic counseling and presymptomatic testing?

Common questions about ABeta amyloidosis, Arctic type